CEBPZ and acute myeloid leukemia: In the 5 year time period from the WHO revision of AML classification in 2008, rates of molecular testing for patients with CBF and normal cytogenetics AML were higher at our academic center versus community referring sites, although rates of molecular testing in the community increased over that time frame.